In Vivo Antibacterial Activity of Dihydroanthracene Disulfonic Acid Derivative in a Case Diagnosed with Necrotizing Fasciitis

This paper focuses on reporting the in vivo antibacterial activity of dihydroanthracene disulfonic acid derivative preparation in a case diagnosed with mixed flora infection with streptococci, enterobacteria, bacterium coli, pseudomonas and anaerobic proteus that resulted in a resistant to ampicillin, piperacillin, ceftazidim, imipenem, and which is moderately sensitive to cotrimoxazole and azithromycin. This resistant infection affected a patient with history of alcohol and tobacco consumption. It later became complicated with Necrotizing Fasciitis after colon cancer surgery. This study is an in vivo study, which is aimed to measure the antibacterial activity of our new preparation against multiresistant mixed bacterial infection. In the situation of this difficult and almost hopeless case, the patient started oral and local treatment with dihydroanthracene disulfonic acid derivative. Although the fatality of the case was due to the antibiotics resistance, the patient's treatment was attributed to the antibacterial effect of the preparation used. A significant improvement was observed in the first 24 hours after the beginning of the treatment. This happened when all parenteral antibiotics were interrupted. The improvement continued and within a couple of weeks, the wounds were clean and with visible granulation. After three months, the wounds cicatrized “per secundam”. In order to have a general conclusion regarding the in vivo study related to the treatment with dihydroanthracene disulfonic acid derivative preparation, other results are needed. The significant effect shown in the above case, demonstrates that this preparation is promising for treating life threatening resistant microorganisms infections. Further studies are needed to evaluate the full pharmacological activity of the new preparation

Cost Savings as a Result of Bortezomib Vial Sharing in Albania

The costs associated with current and emerging therapies, as well as supportive care, are significant and pose a tremendous financial burden to both patients and healthcare system. The objective of this study was to calculate the cost savings as a result of bortezomib vial sharing in the University Hospital Center “Mother Teresa” Tirana. This study was a retrospective analysis of the use of bortezomib in patients with multiple myeloma, using vial sharing technique to minimize wastage. The study has been conducted during the period January 1, 2015 to June 30, 2015 before vial sharing and January 1, 2016 to June 30, 2016 after vial sharing, thereby enabling us to share vial contents between patients. We compared the cost in euro for the treatment with bortezomib in order to determine the cost savings of vial sharing and cost-efficacy of individualised preparation. As a result, the cost savings for one cycle/patient using vial sharing was calculated 226.81 euro, a reduction of 25.96% compared to the period when we did not use vial sharing. During January 1, 2015 to June 30, 2015 the average treatment cost was calculated 873.36 euro/cycle/patient, compared with January 1, 2016 to June 30, 2016 when it was calculated 646.55 euro/cycle/patient. Due to cost savings of each treatment cycle we administered 62 individualised preparations of bortezomib more during January 1, 2016 to June 30, 2016 for the same budget allocated. The same approach should be adopted for other suitable drugs prepared in the University Hospital Center “Mother Teresa” Tirana

Cost Savings as a Result of Bortezomib Vial Sharing in the University Hospital Center „Mother Teresa„ Tirana

The objective of this study was to calculate the cost savings as a result of bortezomib vial sharing in the University Hospital Center “Mother Teresa” Tirana. This study was a retrospective analysis of the use of bortezomib in patients with multiple myeloma, using vial sharing technique to minimize wastage and has been conducted during the period January 1, 2015 to June 30, 2015 before vial sharing and January 1, 2016 to June 30, 2016 after vial sharing. We compared the cost in euro for the treatment with bortezomib. As a result, a reduction of 25.96% was calculated and due to cost savings we administered 62 individualised preparations of bortezomib more during January 1, 2016 to June 30, 2016 for the same budget allocated. The same approach should be adopted for other suitable drugs prepared in the University Hospital Center “Mother Teresa” Tirana